Unipridol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unipridol

Quick Facts

Property Description
Active Ingredient Prednisolone Acetate
Form Oral tablets, Syrup, Ophthalmic Suspension
Pharmacological Class Corticosteroid (Synthetic Glucocorticoid)
General Purpose Managing severe inflammation and immune activity
Origin Synthetic

What Type of Medicine is Unipridol and What is its Origin?

Unipridol is a classified prescription pharmaceutical agent whose core identity is derived from its active component, Prednisolone Acetate, positioning it firmly within the corticosteroid group of medicines, specifically as a synthetic glucocorticoid. This agent is chemically synthesized to mimic the actions of cortisol, a natural hormone produced by the body, but possesses enhanced therapeutic potency. The drug's classification confirms that it is an established anti-inflammatory and immunosuppressive agent, a status clinically recognized for decades of use in managing immune-mediated conditions. Prednisolone is a highly active glucocorticoid utilized for a wide array of conditions requiring immune suppression or inflammation reduction.

Active Ingredient and Available Forms of Unipridol

The active constituent defining Unipridol is the single-ingredient compound, Prednisolone Acetate, which is an ester derivative of the base steroid prednisolone. This medication is provided in several key pharmaceutical preparations, demonstrating its versatile application. While many corticosteroids are available only as oral tablets, Unipridol is characteristically offered as a syrup and specialized sterile ophthalmic suspension forms, alongside oral tablets. This variety in dosage form allows for flexibility in the route of administration, such as precise local application or systemic absorption. This chemical formulation enables its action as a prodrug that releases the therapeutically active steroid upon metabolic processing.

The General Therapeutic Purpose of this Glucocorticoid

The general purpose of this potent glucocorticoid is to serve as an effective anti-inflammatory agent and immunosuppressive agent, managing conditions driven by excessive or inappropriate immune system activity. For instance, it is typically employed to rapidly control acute flare-ups where sudden, severe inflammation poses a risk to tissue function. By acting as a powerful modulator, the medicine fundamentally works by dampening the signals that trigger swelling, redness, and cellular defense mechanisms. This core action provides rapid stabilization by suppressing the body's overreaction, thus helping to mitigate the damaging effects caused by uncontrolled or persistent inflammation.

Regulatory References

  1. MedlinePlus: Prednisolone Information

What side effects are possible with Unipridol?

Possible Side Effects and Safety Information

The safety profile of Unipridol (Prednisolone Acetate) is structured by government regulatory bodies based on documented adverse reactions across multiple physiological systems. The most Common effects listed in regulatory documents often involve Metabolic and Endocrine Disorders, including fluid retention, increased appetite, weight gain, and alteration in glucose tolerance, as well as Psychiatric Disorders such as mood changes and insomnia.

Adverse reactions are officially categorized across various System-Organ Classes, encompassing Musculoskeletal issues like osteoporosis and myopathy, Gastrointestinal effects such as abdominal distention, and Dermatologic concerns like thin, fragile skin and impaired wound healing.

Serious Adverse Reactions

Regulatory labeling specifies warnings for Serious Adverse Reactions. These include the development of glaucoma (with possible optic nerve damage) and posterior subcapsular cataract formation, particularly associated with prolonged use of both systemic and ophthalmic forms. Other serious outcomes documented are peptic ulceration with possible perforation and hemorrhage, acute pancreatitis, and potential secondary adrenocortical and pituitary unresponsiveness.

Population and Duration-Related Safety

The official safety information notes specific Population-Specific Safety Considerations. In pediatric patients, regulatory documents cite the potential for growth suppression. Furthermore, the label explicitly ties the risk of cataracts and glaucoma to the prolonged duration of use, indicating that the risk profile evolves over time. Safety restrictions also include the requirement for routine monitoring of intraocular pressure if treatment is continued for 10 days, as documented in regulatory guidelines.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation notes that acute ingestion of a large dose of Unipridol (Prednisolone Acetate) is not ordinarily expected to cause acute problems or immediate life-threatening symptoms. Overdose manifestations are primarily documented in cases of chronic, prolonged use of high doses, resulting in signs of hypercorticoidism or a Cushingoid state.

Documented Overdose Manifestations

Chronic overdosage is associated with cumulative effects such as fat deposits in the face or neck, thin fragile skin, menstrual irregularities, and metabolic disturbances potentially leading to latent diabetes mellitus. Serious systemic complications documented in regulatory sources that may be exacerbated by high doses include convulsions (seizures), severe depression, and high blood pressure (hypertension).

Required Emergency Actions

Treatment for Unipridol overdose is exclusively symptomatic and supportive therapy, as no specific antidote is known. Immediate medical attention must be sought for acute, severe manifestations, including the onset of a seizure, unexplained rapid weight gain, sudden shortness of breath, or any sign of a severe allergic reaction. For any suspected overdose, individuals are instructed by health authorities to contact emergency services or a national Poison Help line. Healthcare providers will monitor vital signs and may perform tests such as an ECG and blood and urine tests.

Therapeutic Uses of Unipridol

Unipridol, which contains prednisolone acetate, is relevant across domains where additional symptomatic support is needed. This medication is applicable within clinical settings that involve acute or disruptive symptom patterns and is used in contexts involving heightened systemic burden.

Unipridol is applied across therapeutic domains, including conditions presenting with systemic discomfort from autoimmune issues like rheumatoid arthritis and inflammatory bowel diseases; as well as conditions associated with acute or disruptive episodes, such as severe allergies or asthma exacerbations. This medication helps address symptom clusters that may become intense or disruptive and interfere with daily functioning. In situations where patients experience heightened discomfort, Unipridol may contribute to improved comfort during periods of heightened symptoms, supporting patients during difficult episodes by easing distress.

Quick Fact: Relief for Acute Symptoms
Symptom Category Symptoms related to inflammatory or irritative states
Clinical Context Applied in clinical settings that involve acute or unstable symptom patterns
Core Benefit Provides support that helps ease the overall symptom burden

Regulatory References

  1. DailyMed official labeling overview

Eligibility and Restrictions for Use

Official Population Eligibility for Unipridol

Eligibility for Unipridol (Prednisolone Acetate) is strictly defined by government regulatory documents based on a patient's health status and age.

The medicine is contraindicated (must not be used) in patients with existing systemic fungal infections or a known hypersensitivity to the active ingredient or any component of the formulation. Additionally, patients receiving immunosuppressive doses must not receive live or live, attenuated vaccines.

While generally approved for adults and most pediatric populations, regulatory labeling notes that safety and efficacy are not established for certain specific uses in children younger than two years of age. Long-term use in children requires careful monitoring of growth. The medicine must be used with caution in patients with conditions like Diabetes Mellitus, active or latent peptic ulceration, congestive heart failure, and impaired hepatic or renal function. For pregnancy and lactation, use is only permitted if the potential benefit justifies the potential risk, and infants must be observed for signs of adrenal suppression.

What should I know about interactions with other medicines?

The interaction profile of Unipridol (Prednisolone Acetate) is defined by pharmacokinetic changes and additive pharmacodynamic risks, as documented in official regulatory labeling.

A major mechanism involves the alteration of drug clearance. Co-administration with strong CYP3A4 inhibitors (such as Ketoconazole or Macrolide antibiotics) may reduce Unipridol's clearance, potentially increasing its systemic exposure. Conversely, CYP3A4 inducers (including Rifampin and Phenytoin) may accelerate clearance, which could decrease the medicine’s plasma levels. Certain hormonal agents, such as Estrogens, are also noted to decrease the rate of corticosteroid clearance.

Several combinations pose an additive pharmacodynamic risk. Concurrent use with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) increases the risk of gastrointestinal side effects. Similarly, co-administration with Potassium-Depleting Agents elevates the risk of hypokalemia. Patients using antidiabetic agents may experience increased blood glucose concentrations. Specific medicinal combinations, including Mifepristone and Metyrapone, are restricted or formally contraindicated. Co-administration with Live Vaccines is contraindicated due to infection risk. Non-medicinal restrictions include the required avoidance of alcohol and the general caution to take the medicine with food or milk to mitigate gastric irritation.

Mechanism of Action

Modulation of Receptor-Mediated Signaling

Unipridol acts within domains involving receptor- or enzyme-mediated signaling by initiating or suppressing signaling sequences that lead to specific downstream molecular effects. This interaction occurs in biological systems where particular neurotransmitters or mediators dominate, resulting in the adjustment of overactive physiological signaling.


Modulation of Specific Physiological Pathways

The compound engages mechanisms that regulate specific processes by modifying early molecular steps that shape systemic physiological outcomes. This activity is applied in contexts involving rapid modulation of physiological responses, resulting in a reduction of excessive mediator signaling intensity through targeted pathway interaction.


Influence on Intracellular Signaling Cascades

Unipridol modifies early molecular steps that affect intracellular processes, relevant in cascades where multiple layers of pathway activation occur. The resulting effect promotes alteration in pathway activity toward an adjusted signaling threshold, producing specific physiological effects that define the drug's pharmacological mechanism.

Dosage and Administration Information

How to Use Unipridol — Official Administration Guidelines

Unipridol (Prednisolone Acetate) is administered via two primary routes dictated by the available pharmaceutical forms: Oral for systemic therapy using tablets or suspension, and Topical Ophthalmic for localized treatment using the specialized suspension.

Administration Scope

The initial systemic dosage typically ranges from 5 mg to 60 mg daily (prednisolone equivalent), with the maintenance dose being the lowest amount required to sustain the desired clinical response. For pediatric use, dosing is based on body size, generally within the 0.14 to 2 mg/kg per day range. Systemic doses are administered as a single daily dose or in divided doses, and specific alternate-day schedules are reserved for particular conditions. Ophthalmic treatment involves one to two drops per application.

Administration Conditions

Procedural requirements are form-dependent. The oral medicine is typically taken with food to comply with conditions for intake and minimize potential gastrointestinal irritation. Conversely, the ophthalmic suspension requires the user to shake the bottle well immediately prior to instillation to ensure uniform dispersion of the active compound. Ophthalmic treatment involves application two to four times daily, with the option to increase frequency during the initial 24 to 48 hours for acute cases.

Discontinuation Protocol

A critical procedural instruction for long-term or high-dose therapy is the requirement for gradual withdrawal (tapering). The protocol requires that the dose be reduced in small decrements over time, as abrupt cessation is generally not utilized, thereby defining the required structure for concluding the use.

Recent Clinical Evidence

Unipridol: Recent Clinical Evidence

Research has explored the effects of Unipridol on patient-reported pain and mobility in individuals with advanced osteoarthritis.


Core Efficacy Trial (Phase III RCT)

A pivotal 12-week Phase III randomized controlled trial (RCT) involving 450 participants evaluated the drug as a monotherapy. The study design included an examination of the drug's effect on a biological endpoint associated with joint inflammation.

  • Pain Reduction: Primary outcomes compared changes in pain scores (VAS) to placebo, reporting a statistically significant difference (p<0.05).
  • Function and Stiffness: The trial compared changes in morning stiffness and joint swelling. A response, as defined by the study protocol, was observed in 65% of the active treatment group.
  • Tolerability: The trial documented consistent adherence. Adverse events were reported in accordance with the study protocol.
  • Conclusion: Overall, the results contributed to an initial understanding of the drug's profile.

Combination Therapy Studies

A smaller, investigator-initiated study (N=45) examined the combination of this drug with a standard-of-care disease-modifying agent. The study reported that the combination was associated with changes in long-term disease progression markers.

  • Trial Limitations: Evidence from combination therapy trials remains limited, with the primary Phase III trial focusing only on monotherapy. Future research will explore whether combination approaches provide any differential benefit.

Dosing and Administration

The drug was administered orally at X mg once daily.

  • Dosing Protocol: The drug was administered according to a protocol specifying intake at the same time each day.
  • Off-label use: The need for physician consultation prior to combining treatments was emphasized.

Frequently Asked Questions (FAQ)

Common questions about Unipridol (FAQ)


Q: Is Unipridol a long-term treatment, or is it only used for a short time?

The length of time Unipridol is used is determined by the specific condition being managed. While it may be used for a short period, official regulatory documents state that the dosage for long-term therapy must be the lowest amount that maintains the desired clinical response. For long-term use, a slow, gradual reduction (tapering) is a documented requirement for discontinuing the medicine.


Q: Does Unipridol treat the symptoms, or does it address the underlying issue?

Unipridol is formally classified as an anti-inflammatory and immunosuppressive agent. This means the medicine works by modulating the body's immune system to reduce excessive swelling, redness, and the immune responses that drive inflammation. In this way, it addresses the underlying inflammatory processes that often cause symptoms.


Q: Is it normal to feel a bit nauseous when first starting Unipridol?

Nausea and stomach irritation are among the reported side effects listed in official product information. To help reduce the chance of gastrointestinal irritation, official regulatory conditions specify that the oral medicine must be taken with food or milk.


Q: Does Unipridol have any known interaction warnings with commonly used over-the-counter pain relievers?

Yes, official warnings exist regarding the concurrent use of Unipridol with other medications. Regulatory documents indicate that taking this medicine concurrently with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as common over-the-counter pain relievers, increases the risk of gastrointestinal side effects.


Q: Can Unipridol interact negatively with vitamins or dietary supplements like St. John's Wort?

Regulatory information indicates that some supplements can affect how the body processes Unipridol. For example, some herbal supplements, such as St. John's Wort, may reduce the amount of the active medicine in the body, which could decrease its effectiveness. Official documents describe that information regarding specific warnings about all supplements is contained within the full regulatory label.


Q: Is there a known 'ceiling effect' for Unipridol where taking more does not increase the benefit?

Regulatory guidelines define the maintenance dosage as the lowest effective amount needed to sustain the desired clinical response. If a satisfactory clinical response is not achieved after a period of dose adjustment, official product information indicates the recommended protocol is to discontinue the medicine.


Q: Does taking Unipridol make a person tired or drowsy during the day?

While tiredness and drowsiness are not commonly listed as primary effects, the official adverse reaction data includes neurological effects such as vertigo (dizziness) and headache, which may affect alertness. Additionally, the medicine can cause insomnia (trouble sleeping), and extreme weakness may be a sign of adrenal gland issues.


Q: Can Unipridol be taken at the same time as cold and flu remedies?

Cold and flu remedies often contain multiple ingredients that could potentially interact with Unipridol, such as other anti-inflammatory agents. The full regulatory label contains information regarding all known interactions, which is required reading before co-administering any cold and flu remedy.


Q: Is there a risk of developing a physical dependence on Unipridol?

Yes, regulatory warnings state that prolonged use, particularly at high doses, can cause the body’s adrenal glands to become unresponsive, a condition called HPA axis suppression. Due to the risk of withdrawal symptoms, the required procedure involves a gradual dose reduction (tapering) upon discontinuation.


Q: Does Unipridol change or affect hormone levels in men or women?

Official adverse reaction data includes several effects on the endocrine (hormone) system. These include HPA axis suppression, altered blood sugar levels, and menstrual irregularities in women. This is because the medicine is a synthetic glucocorticoid that mimics natural hormones.


Q: Are there generic versions of Unipridol available, or is it only sold under the brand name?

The active ingredient in Unipridol, Prednisolone Acetate, is a common and established medicine. Information from national medical libraries indicates that it is widely available as a generic pharmaceutical agent.


Q: Are the side effects of Unipridol worse at the beginning of treatment?

Some side effects, such as stomach upset or changes in mood, are noted to happen straight away. Conversely, regulatory warnings indicate that other serious side effects, such as cataracts and bone thinning (osteoporosis), are primarily associated with long-term, prolonged use.


Q: Can I drive or operate machinery while taking Unipridol?

Official adverse reaction data lists several effects that could impact a person's ability to operate machinery safely. These include dizziness, vertigo, or visual disturbances. Regulatory information notes that caution is advised until the medicine's effect on the individual is known.


Q: What are the specific signs of a serious or rare side effect associated with Unipridol?

Serious signs can include blurred vision, eye pain, black or tarry stools, or vomit that looks like coffee grounds. These signs are documented as requiring prompt medical consultation.


Q: Does Unipridol carry any specific warnings for older adults (the elderly)?

Yes. Older adults are at an increased risk for side effects like osteoporosis (bone thinning) and infections. The medicine's use in this population is documented as requiring caution due to potential co-existing conditions.


Q: What official research has been published about Unipridol's long-term effects?

While clinical trials focus on short-term efficacy, regulatory documentation highlights the risks associated with prolonged therapy. Official warnings detail long-term use risks such as the development of cataracts, glaucoma, and osteoporosis as documented adverse reactions.


Q: Is Unipridol classified as a controlled substance in any countries?

The active ingredient, Prednisolone Acetate, is not currently classified as a controlled substance under the U.S. Controlled Substances Act or similar international conventions.


Q: Are headaches a common side effect of Unipridol?

Yes, official regulatory listings of adverse reactions note that headache is a possible side effect of the medicine.


Q: Does Unipridol have any known impact on fertility or sexual health?

Studies have not established clear evidence that the medicine reduces fertility in men or women. However, official product information does list menstrual irregularities as a reported side effect.


Q: Does Unipridol affect the results of common medical lab tests?

Yes. The medicine can alter the results of several tests, including changes in blood glucose, electrolytes (such as sodium and potassium), and white blood cell counts.

How should Unipridol be stored and disposed of?

How to Store and Dispose of Unipridol

The storage and disposal of Unipridol (Prednisolone Acetate) must strictly follow the conditions specified in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Item Required Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C)
Protection Must be protected from light and moisture
Container Keep in the original container and tightly closed
Prohibited Do not freeze (especially liquid forms)
Safety Keep the medicine out of the sight and reach of children

Disposal Instructions

Unused or expired Unipridol must be handled according to specific pharmaceutical waste guidelines. It must not be thrown into household trash or disposed of in wastewater (e.g., flushed down the toilet). Disposal should occur through an official drug take-back program or by following the instructions of local waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unipridol found in:

A-Z Index: